FACE TO FACE: Dr Prabuddha Kundu, Managing Director, Premas Biotech

Dr Prabuddha Kundu, Co-founder & Managing Director, Premas Biotech recently on the sidelines of Global Bio India 2024 in New Delhi shared his insights on his company focus on global collaborations, industry's key growth drivers, India's US$ 300 billion bioeconomy target by 2030 and much more.

By Rahul Koul -
0
504
In an exclusive rapid-fire interview on the sidelines of Global Bio India 2024 in New Delhi, Rahul Koul, Chief Editor, BioVoice News spoke to Dr Prabuddha Kundu, Co-founder & Managing Director, Premas Biotech. Dr Kundu shared his insights on how his company has partnered with global companies on path-breaking technologies, India’s US$ 300 billion bioeconomy by 2030 and much more.
In the recent past, Premas Biotech has entered into partnership with Oramed Inc., as only manufacturer of the proteins required for Oral Insulin, which has successfully cleared Phase IIb trials in the US. The company has worked on more than 650 proteins for the top 20 pharma and biotech organizations across the world.
Key Questions
♦ Premas Biotech is well known for its global collaborations. How has it propelled the growth of the company’s growth in the last few years?
♦ How has the Indian biotechnology market changed over last decade and with it the investor outlook? Your broader perspective?
♦ There is a lot of thrust on biomanufacturing within the recently launched BIOE3 policy. How do you look at this policy and the broader US$ 300 billion bioeconomy by 2030?
♦ Your future outlook for the company and bioscience market in India?
About Dr Prabuddha Kundu:
With over 26 years of experience, Dr Prabuddha Kundu is the brain behind the indigenous developed innovative processes and technologies for effective protein manufacturing. He has established technology platforms for production and testing of novel biologics and vaccines. He has also developed bioprocesses and production plants for therapeutics, vaccines and blood derived products. He has a strong specialization in process development & scaleup for biologics including MAbs.
He holds a Ph.D. in Biomedical Engineering from the Indian Institute of Technology-Bombay, and has interests in protein engineering, bioprocess development, lean transformation, and emerging technologies. Dr Kundu began his career at Bio-Rad (India, Asia-Pacific), before moving to Ranbaxy (India) and then co-founded Premas in 2006.
Click here now to watch the full interview for detailed insights.

RELATED ARTICLESMORE FROM AUTHOR